Dr. Thompson on Exciting Advancements in the Field of Multiple Myeloma

Michael A. Thompson, MD, PhD
Published: Monday, Dec 05, 2016

Michael A. Thompson, MD, PhD, medical director, precision medicine, Vince Lombardi Cancer Clinic, Aurora Health Care, discusses some of the recent exciting advancements in the field of multiple myeloma during the American Society of Hematology (ASH) Annual Meeting.
Last year was a very exciting year for the field of multiple myeloma, Thompson says, with many new drugs approved to treat the disease, including daratumumab (Darzalex). This year is about sorting out how to best use those drugs.
Recent study findings have confirmed the efficacy of daratumumab long-term, which is very exciting, Thompson says. Now, researchers are starting to investigate the drug in combination studies.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication